This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
ROCKVILLE, Md., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the clinical data that was released at the American Epilepsy Society (AES) Meeting in December in Washington DC is now available on its website.
Please click here to view.
In total, Supernus had 12 presentations/scientific posters highlighting data that were generated on Trokendi XR and Oxtellar XR.
For a complete read on the data and scientific posters please refer to the link above or go to our website under the investor and events & presentations section.
Some of the key and exciting highlights from the data include:
An overwhelming majority of patients (93%) preferred once daily Trokendi XR when switched from twice daily immediate release topiramate. Similarly, 92% of the patients with epilepsy also expect Trokendi XR to have a positive impact on treatment adherence.
In a head to head study, once daily Trokendi XR was bioequivalent to twice daily immediate release topiramate and showed a potential pharmacodynamic difference with a significantly less negative impact on objective measures of cognitive function such as verbal fluency (i.e., Controlled Oral Word Association, COWA).
Trokendi XR offers the convenience of once-daily topiramate dosing without increasing the clinical risk of missed, delayed, or doubled doses.
Co-administration of Trokendi XR with alcohol in humans does not result in "dose dumping." Patients will have similar systemic exposure whether Trokendi XR is taken with or without alcohol.
Dosage recommendations for Trokendi XR in elderly patients are the same as for immediate release topiramate , i.e., reduce dose according to renal function status rather than age (one-half the adult dose if creatinine clearance < 70mL/min/1.73m
Seizure control achieved with once-daily Oxtellar XR during the double-blind PROSPER study was maintained and further improved during the long term open-label extension when dosages could be optimized. Oxtellar XR showed impressive median % seizure reduction up to 64% with responder rates (% of patients with > 50% seizure reduction) overtime up to 61%.